Presentation is loading. Please wait.

Presentation is loading. Please wait.

Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer  Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,

Published byEmily Goodman Modified over 5 years ago

Similar presentations

Presentation on theme: "Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer  Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,"— Presentation transcript:

1 Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer 
Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi, MD, Koichi Fukumoto, MD, Shota Nakamura, MD, Shuhei Hakiri, MD, Naoki Ozeki, MD, Kohei Yokoi, MD  The Annals of Thoracic Surgery  Volume 101, Issue 5, Pages (May 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Overall survival curves of the cohort stratified by pathologic stage. The cumulative 5-year survival rate of each stage is shown. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 The changes of 5Y-CS based on (A) overall survival, (B) lung cancer–specific survival, and (C) recurrence-free survival. In this study, 5Y-CS(x) was defined as the survival probability of the next 5 years at some years after operation (x). The 5Y-CS(1), 5Y-CS (2), 5Y-CS(3), and 5Y-CS(4) in all patients showed gradual improvement. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 The change in 5Y lung cancer–specific CS when adjusted for (A) age, (B) sex, (C) histologic type, or (D) smoking status. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 The changes of 5Y-CS(0), 4Y-CS(1), 3Y-CS(2), 2Y-CS(3), and 1Y-CS(4) based on (A) overall survival, (B) lung cancer–specific survival, and (C) recurrence-free survival. These factors were defined as the probability of surviving at 5 postsurgical years after a specific time. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

6 Fig 5 (A and B) The change in 5Y-CS and 5Y-CS(0), 4Y-CS(1), 3Y-CS(2), 2Y-CS(3), and 1Y-CS(4) in women and those with adenocarcinoma histologic type, pathologic stage I, and normal serum carcinoembryonic antigen (CEA) levels (red). These same factors in male patients with squamous cell carcinoma are shown in blue. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer  Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,"

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E
Elizabeth A. David, MD, David T

Elizabeth A. David, MD, David T
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival  Elizabeth A. David, MD, Robert J. Canter,

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival  Elizabeth A. David, MD, Robert J. Canter,
Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,
Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A

Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A
Chun Chieh Lin, PhD, MBA, Matthew P

Chun Chieh Lin, PhD, MBA, Matthew P
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Oncologic Outcomes After Surgical Resection of Subcentimeter Non-Small Cell Lung Cancer  Matthew J. Schuchert, MD, Arman Kilic, BS, Arjun Pennathur, MD,

Oncologic Outcomes After Surgical Resection of Subcentimeter Non-Small Cell Lung Cancer  Matthew J. Schuchert, MD, Arman Kilic, BS, Arjun Pennathur, MD,
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,
Prognostic Factors Associated With Interventional Bronchoscopy in Lung Cancer  Nicolas Guibert, MD, Julien Mazieres, MD, PhD, Benoît Lepage, MD, Gavin.

Prognostic Factors Associated With Interventional Bronchoscopy in Lung Cancer  Nicolas Guibert, MD, Julien Mazieres, MD, PhD, Benoît Lepage, MD, Gavin.
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Similar presentations

Ads by Google